Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00607997 · ClinicalTrials.gov registry record · Phase 2
Study of Voreloxin (Vosaroxin) in Older Patients With Untreated Acute Myeloid Leukemia
A Phase 2 study of Acute Myeloid Leukemia and Leukemia, sponsored by Sunesis Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 113
- Enrollment target
- 20
- Study locations
NCT00607997 is a Phase 2 study of Acute Myeloid Leukemia and Leukemia that has completed, run by Sunesis Pharmaceuticals. The registered enrollment target is 113 participants, roughly in line with the 115-participant average among 306 other Acute Myeloid Leukemia trials with a reported enrollment target. The trial reports 20 study locations across 15 states.
The verdict
NCT00607997, a Phase 2 study of Acute Myeloid Leukemia and Leukemia, has completed, sponsored by Sunesis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 113 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study will evaluate the overall remission rate of treatment with vosaroxin (formerly voreloxin) Injection in patients at least 60 years of age with previously untreated AML
Conditions Studied
Interventions
- DRUG vosaroxin
Study Locations (20)
Arizona
- Mayo Clinic Hospital - Phoenix
- Mayo Clinic Scottsdale - Scottsdale
Illinois
- Rush University Medical Center - Chicago
- The University of Chicago - Chicago
Indiana
- Indiana University Cancer Center - Indianapolis
- St. Francis Hospital & Health Systems at Beech Grove Campus - Indianapolis
Kansas
- Cancer Center of Kansas - Wichita
- Cancer Center of Kansas - Wichita
Massachusetts
- Massachusetts General Hospital - Boston
- Dana-Farber Cancer Institute - Boston
California
- Scripps Cancer Center - La Jolla
Colorado
- Rocky Mountain Blood and Marrow Transplant Program - Denver
Louisiana
- LSU Health Sciences Center at Shreveport - Shreveport
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 113 participants |
| Start Date | 2008-05-15 |
| Est. Completion | 2009-11-23 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00607997
The ClinicalTrials.gov registry entry for NCT00607997 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 113 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 115-participant average among 306 other Acute Myeloid Leukemia trials with a reported enrollment target. The listed sponsor is Sunesis Pharmaceuticals, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 5 conditions, with Acute Myeloid Leukemia appearing as the primary indexed condition, and to 1 intervention - of which vosaroxin is the first listed.
NCT00607997 reports 20 study locations spanning 15 distinct geographic areas - top geographies include Arizona, Illinois, Indiana.
Frequently Asked Questions
What is clinical trial NCT00607997 about?
NCT00607997 is a clinical study titled "Study of Voreloxin (Vosaroxin) in Older Patients With Untreated Acute Myeloid Leukemia". This study will evaluate the overall remission rate of treatment with vosaroxin (formerly voreloxin) Injection in patients at least 60 years of age with previously untreated AML
What is the current status of trial NCT00607997?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 113 participants. The study started on 2008-05-15. Estimated completion is 2009-11-23.
What conditions does trial NCT00607997 study?
This clinical trial studies the following conditions: Acute Myeloid Leukemia, Leukemia, Myelodysplastic Syndromes, Acute Disease, Nonlymphocytic Leukemia.
What interventions are being tested in trial NCT00607997?
The interventions under investigation include: vosaroxin (DRUG).
Who is sponsoring clinical trial NCT00607997?
This trial is sponsored by Sunesis Pharmaceuticals, which has 13 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00607997 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Illinois, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Acute Myeloid Leukemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Azacitidine or Decitabine With Venetoclax for Acute Myeloid Leukemia With Prior Hypomethylating Agent Failure
RECRUITING · Phase 2
-
Venetoclax + Azacitidine vs. Induction Chemotherapy in AML
RECRUITING · Phase 2
-
A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
RECRUITING · Phase 2
-
Evaluation of Two Dose Levels of Quizartinib as Maintenance in FLT3-ITD (+) Acute Myeloid Leukemia Patients in Complete Remission
RECRUITING · Phase 2
-
A Study of Tagraxofusp in Combination With Venetoclax and Azacitidine in Adults With Untreated CD123+ Acute Myeloid Leukemia Who Cannot Undergo Intensive Chemotherapy
RECRUITING · Phase 2
-
Venetoclax, Cladribine, Low Dose Cytarabine, and Azacitidine in Treating Patients With Previously Untreated Acute Myeloid Leukemia
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.